Neurological comorbidity and epilepsy: Implications for treatment

Acta Neurologica Scandinavica

Volumn 120, Issue 1, 2009, Pages 1-15

  Zaccara, G ^a  

^a Palagi Hospital   (Italy)

Author keywords

Antiepileptic drugs; Co morbidity; Drug interactions; Epilepsy

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; FELODIPINE; GABAPENTIN; LAMOTRIGINE; METHYLPHENIDATE; MODAFINIL; NISOLDIPINE; OXCARBAZEPINE; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; WARFARIN; ZONISAMIDE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EPILEPSY; HUMAN; MENTAL DEFICIENCY; MIGRAINE; MULTIPLE SCLEROSIS; REVIEW; SLEEP APNEA SYNDROME;

ANTICONVULSANTS; BRAIN DISEASES; DRUG INTERACTIONS; EPILEPSY; HUMANS;

EID: 66849113708     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01146.x     Document Type: Review

References (113)

1. Feinstein AR. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis 1973 23 : 455 69.
2. Tellez-Zenteno JF, Matijevic S, Wiebe S. Somatic comorbidity of epilepsy in the general population in Canada. Epilepsia 2005 46 : 1955 62.
3. Jalava M, Sillampaa M. Concurrent illnesses in adults with childhood-onset epilepsy: a population-based 35-years follow up study. Epilepsia 1996 37 : 1155 63.
4. Gaitatzis A, Carroll K, Majeed A, Sander JW. The epidemiology of the comorbidity in epilepsy in the general population. Epilepsia 2004 45 : 1613 22.
5. Nuyen J, Schellevis FG, Satariano WA et al. Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol 2006 59 : 1274 84.
6. Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006 67 (Suppl. 4 S39 44.
7. Ettinger AB. Psychotropic effects of antiepileptic drugs. Neurology 2006 67 : 1916 25.
8. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders. Relations between mechanisms of actions and clinical efficacy. CNS Drugs 2008 22 : 27 47. (Pubitemid 350243365)
9. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota. 1935-1984. Epilepsia 1993 34 : 453 68.
10. Ryvlin P, Montavont A, Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology 2006 67 (Suppl. 4 S3 9.
11. Szaflarsky JP, Rackley AY, Kleindorfer DO et al. Incidence of seizures in the acute phase of stroke: a population-based study. Epilepsia 2008 49 : 974 81.
12. Lossius MI, Rønning OM, Slapø GD et al. Poststroke epilepsy: occurrence and predictors - a long-term prospective controlled study (Akershus Stroke Study). Epilepsia 2005 46 : 1246 51.
13. Hack W, Kaste M, Bogousslavsky J et al. European stroke initiative recommendations for stroke management: update 2003. Cerebrovasc Dis 2003 16 : 311 37.
14. Broderick JP, Adams HP Jr., Barsan W et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for health care professionals from a special writing group of the Stroke Council, American Health association. Stroke 1999 30 : 905 15.
15. Gilad R, Sadeh M, Rapaport A et al. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clin Neuropharmacol 2007 30 : 189 95.
16. Alvarez-Sabin J, Montaner J, Padro L et al. Gabapentin in late-onset poststroke seizures. Neurology 2002 59 : 1991 3.
17. Stephen LJ, Kwan P, Brodie MJ. Does the cause of localization-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 2001 42 : 357 62.
18. Cloyd J, Hauser W, Towne A et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res 2006 68 (Suppl. 1 S39 48.
19. Zaccara G, Cincotta M, Borgheresi A, Balestrieri F. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord 2004 6 : 153 68.
20. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic rugs. Epilepsia 2007 48 : 1223 44.
21. Eirís JM, Lojo S, Del Río MC et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995 45 : 1155 7.
22. Sonmez FM, Demir E, Orem A et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol 2006 21 : 70 4.
23. Isojärvi JI, Pakarinen AJ, Myllylä VV. Serum lipid levels during carbamazepine medication. A prospective study. Arch Neurol 1993 50 : 590 3.
24. Pita-Calandre E, Rodriguez-Lopez CM, Cano MD, Pena-Bernal M. Serum lipids. lipoproteins, and apolipoproteins in adult epileptics treated with carbamazepine, valproic acid, or Phenytoin. Rev Neurol 1998 27 : 785 9.
25. Apeland T, Mansoor MA, Strandjord RE. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 2001 47 : 27 35. (Pubitemid 32973645)
26. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994 78 : 117 41.
27. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005 65 : 1976 8.
28. Steinhoff BJ. Optimizing therapy of seizures in patients with endocrine disorders. Neurology 2006 67 (Suppl. 4 S23 7.
29. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003 2 : 473 81.
30. Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 1993 15 : 39 42. (Pubitemid 23040314)
31. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2005 61 : 246 55.
32. Levy RH, Collins C. Risk and predictability of drug interactions in the elderly. Int Rev Neurobiol 2007 81 : 235 51.
33. Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006 47 : 1094 120.
34. Zaccara G, Gangemi PF, Cincotta M. Central Nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008 17 : 405 21.
35. Mendez MF, Lim GTH. Seizures in elderly patients with dementia, Epidemiology and management. Drugs Ageing 2003 20 : 791 803. (Pubitemid 37159597)
36. Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology 1986 36 : 1226 30.
37. Rowan AJ. Management of seizures in the elderly. Pharamcotherapy 2000 20 : 178S 84S.
38. Volicer L, Smith S, Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia 1995 6 : 258 63.
39. Belcastro V, Costa C, Galletti F et al. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol 2007 14 : 1176 8.
40. Tariot PN, Erb R, Podgorski CA et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998 155 : 54 61. (Pubitemid 28037549)
41. Moretti R, Torre P, Antonello RM et al. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging 2003 20 : 1035 40.
42. Porsteinsson AP, Tariot PN, Jakimovich LJ et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am J Geriatr Psychiatry 2003 11 : 434 40.
43. Pellock JM, Morton LD. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil Res Rev 2000 6 : 309 26.
44. Smith MC. Optimizing therapy of seizures in children and adolescents with developmental disorders. Neurology 2006 67 (Suppl. 4 S52 5.
45. Kerr MP, Baker GA, Brodie MJ. A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Epilepsy Behav 2005 7 : 472 80.
46. Crawford P, Brown S, Kerr M, Parke Davis Clinical Trials Group. A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure 2001 10 : 107 15.
47. Mikati MA, Choueri R, Khurana DS, Riviello J, Helmers S, Holmes G. Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res 1998 42 (Suppl. 1 57 62.
48. McKee JR, Sunder TR, Vuong A, Hammer AE. Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. J Child Neurol 2006 21 : 372 9.
49. Opp J, Tuxhorn I, May T et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005 14 : 476 84.
50. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res 1998 42 (Suppl. 1 41 5.
51. Arvio M, Sillanpää M. Topiramate in long-term treatment of epilepsy in the intellectually disabled. J Intellect Disabil Res 2005 49 : 183 9.
52. Iinuma K, Minami T, Cho K, Kajii N, Tachi N. Long-term effects of zonisamide in the treatment of epilepsy in children with intellectual disability. J Intellect Disabil Res 1998 42 (Suppl. 1 68 73.
53. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006 114 : 157 68.
54. Aldenkamp AP, Arzimanoglou A, Reijs R, Mil SA. Optimizing therapy of seizures in children and adolescents with ADHD. Neurology 2006 67 (Suppl. 4 S49 51.
55. Dunn D, Austin J, Harezlak J, Ambrosius W. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003 45 : 50 4.
56. Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 1993 8 : 19 27. (Pubitemid 23039225)
57. Smoot LC, Boothby LA, Gillett RC. Clinical assessment and treatment of ADHD in children. Int J Clin Pract 2007 61 : 1730 8.
58. Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-deficit/ hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 2008 12 : 217 33.
59. Olafsson E, Ludvigsson P, Gudmundsson G et al. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol 2005 4 : 627 34.
60. Van Breemen MSM, Wilms E, Vecht CJ. Epilepsy in patients with brain tumors: epidemiology, mechanisms, and management. Lancet Neurol 2007 6 : 421 30.
61. Singh G, Rees JH, Sander W. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry 2007 78 : 342 9.
62. Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommitee of the American Academy of Neurology. Neurology 2000 54 : 1886 93.
63. Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumours. Cochrane Database Syst Rev 2008 Issue 2. Art. No.: CD004424. DOI :.
64. Hildebrand J. Management of epileptic seizures. Curr Opin Oncol 2004 16 : 314 7.
65. Moots PL, Maciunas RJ, Eisert DR et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995 52 : 717 24.
66. Sisodiya SM, Lint WR, Harding BN et al. Drug resistance in epilepsy: human epilepsy. Novartis Found Symp 2002 243 : 167 74.
67. Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006 67 (Suppl. 4 S10 3.
68. Wick W, Menn O, Mesner C et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 2005 28 : 391 6.
69. Newton HB, Goldhust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of Levetiracetam in brain tumour patients. J Neurooncol 2006 78 : 99 102. (Pubitemid 43786667)
70. Siddiqui F, Wen P, Dworetzlky B et al. Use of Levetiracetam in patients with brain tumours. Epilepsia 2002 43 (Suppl. 7 297.
71. Wagner GL, Wilms EB, Van Doselaar CA, Vecht C. Levetiracetam preliminary experience in patients with primary brain tumours. Seizure 2003 12 : 585 6.
72. Maschio M, Albani F, Baruzzi A et al. Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 2006 80 : 97 100. (Pubitemid 44473268)
73. Perry JR, Sawka C. add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 1996 23 : 128 31.
74. Maschio M, Dinapoli L, Zarabla A et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 2008 86 : 61 70. (Pubitemid 350263434)
75. Khafaga YM, Jamshed A, Allam AA et al. Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy. Acta Oncol 1999 38 : 111 6.
76. Micali G, Linthicum K, Han N, West DP. Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy 1999 19 : 223 7.
77. Michelucci R. Optimizing therapy of seizures in neurosurgery. Neurology 2006 67 : S14 8.
78. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic agents. Lancet Neurol 2003 2 : 404 9.
79. Oberndorfer S, Piribauer M, Marosi C et al. P450 enzyme-inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005 72 : 255 60.
80. Lackner TE. Interaction of dexamethasone with phenytoin. Pharmacotherapy 1991 11 : 344 7.
81. Sander JW, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta Neurol Scand 2003 108 : 16 22.
82. Preux PM, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol 2005 4 : 21 31. (Pubitemid 40023233)
83. Bhigjee AI, Rosemberg S. Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology 2006 67 (Suppl. 4 S19 22.
84. Tohiama M, Hashimoto K, Yasukawa M et al. Association of human herpesvirus-6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Clin Lab Invest 2007 157 : 934 40.
85. Shiohara T, Iijima M, Ikezawa Z et al. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivation. Br J Dermatol 2007 156 : 1083 4.
86. Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2006 155 : 344 9.
87. Jennings HR, Romanelli F. The use of valproic acid in HIV positive patients. Ann Pharmacother 1999 33 : 1113 6.
88. Hantson PH, Léonard F, Maloteaux JM et al. How epileptogenic are the recent antibiotics? Acta Clin Belg 1999 54 : 80 7.
89. Hugen PW, Burger DM, Brinkman K et al. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000 34 : 465 70.
90. Barry M, Gibbons S, Back D et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic consideration. Clin Pharmacokinet 1997 32 : 194 209. (Pubitemid 27122520)
91. Epilepsy and HIV - a dangerous combination. Lancet Neurol 2007 6 : 747.
92. Anderman E, Anderman FA. Migraine-epilepsy relationship: epidemiological and genetic aspects. In : Anderman FA, Lugaresi E, eds. Migraine and epilepsy. Boston, MA : Butterworths, 1987 281 91.
93. Marks DA, Ehrenberg BL. Migraine related seizures in adults with epilepsy, with EEG correlation. Neurology 1993 43 : 2476 83.
94. Piccinelli P, Borgatti R, Nicoli F et al. Relationship between migraine and epilepsy in pediatric age. Headache 2006 46 : 413 21.
95. De Simone R, Ranieri A, Marano E et al. Migraine and epilepsy: clinical and pathophysiological relations. Neurol Sci 2007 28 : S150 5.
96. Calabresi P, Galletti F, Rossi C et al. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007 28 : 188 95.
97. Young T, Palta M, Dempsey J et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993 328 : 1230 5.
98. Chihorek AM, Abou-Khalil B, Malow BA. Obstructive sleep apnea is associated with seizure occurrence in older adults with epilepsy. Neurology 2007 69 : 1823 7.
99. Hollinger P, Khatami R, Gugger M, Hess CW, Bassetti CL. Epilepsy and obstructive sleep apnea. Eur Neurol 2006 55 : 74 9.
100. Benbadis SR. CPAP. A treatment for epilepsy? Neurology 2007 69 : 1814 5.
101. Brust JCM. Seizures and substance abuse: treatment considerations. Neurology 2006 67 (Suppl. 4 S45 8.
102. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence. CNS Drugs 2005 19 : 873 96.
103. Johnson BA. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav 2004 29 : 1465 79.
104. Johnson BA, Ait-Daoud N, Akhtar FZ et al. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals. Arch Gen Psychiatry 2004 61 : 905 12.
105. Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine addition. CNS Drugs 2005 19 : 13 25. (Pubitemid 40165154)
106. Gonzales G, Sevarino K, Sofuoglu M et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomised clinical study. Addiction 2003 98 : 1625 32.
107. Olafsson E, Benedikz J, Hauser WA. Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia 1999 40 : 745 7.
108. Nicoletti A, Sofia V, Biondi R et al. Epilepsy and multiple sclerosis in Sicily: a population-based study. Epilepsia 2003 44 : 1145 8.
109. Koch M, Uyttenboogaart M, Polman S, De Keiser J. Seizures in multiple sclerosis. Epilepsia 2008 49 : 948 53.
110. Ruffmann C, Bogliun G, Beghi E. Epileptogenic drugs: a systematic review. Expert Rev Neurother 2006 6 : 575 89.
111. Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol 2008 28 : 56 68.
112. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005 28 : 72 8.
113. Lacerda G, Krummel T, Sabourdy C et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006 67 (Suppl. 4 S28 33.